MA56132A - Procédés de purification d'anticorps et compositions associées - Google Patents

Procédés de purification d'anticorps et compositions associées

Info

Publication number
MA56132A
MA56132A MA056132A MA56132A MA56132A MA 56132 A MA56132 A MA 56132A MA 056132 A MA056132 A MA 056132A MA 56132 A MA56132 A MA 56132A MA 56132 A MA56132 A MA 56132A
Authority
MA
Morocco
Prior art keywords
methods
purifying antibodies
associated compositions
compositions
antibodies
Prior art date
Application number
MA056132A
Other languages
English (en)
Inventor
Michael E Dolan
Lutfiye Kurt
Sheldon F Oppenheim
George Parks
Norbert Schuelke
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MA56132A publication Critical patent/MA56132A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/145—Extraction; Separation; Purification by extraction or solubilisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA056132A 2019-06-10 2020-06-10 Procédés de purification d'anticorps et compositions associées MA56132A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962859580P 2019-06-10 2019-06-10

Publications (1)

Publication Number Publication Date
MA56132A true MA56132A (fr) 2022-04-13

Family

ID=73782230

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056132A MA56132A (fr) 2019-06-10 2020-06-10 Procédés de purification d'anticorps et compositions associées

Country Status (14)

Country Link
US (1) US20220259291A1 (fr)
EP (1) EP3980119A4 (fr)
JP (2) JP7753105B2 (fr)
CN (4) CN114025843B (fr)
AR (1) AR119268A1 (fr)
AU (1) AU2020290999A1 (fr)
BR (1) BR112021024848A2 (fr)
CA (1) CA3143169A1 (fr)
IL (1) IL288830A (fr)
MA (1) MA56132A (fr)
MX (1) MX2021015302A (fr)
PL (1) PL439807A1 (fr)
TW (1) TW202112800A (fr)
WO (1) WO2020252072A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019198099A1 (fr) * 2018-04-10 2019-10-17 Dr. Reddy's Laboratories Limited Formulation d'anticorps stable
EP4380948A4 (fr) * 2021-08-05 2025-07-16 Dr Reddys Laboratories Ltd Procédé de purification d'une composition d'anticorps au moyen d'une chromatographie par échange de cations
WO2023031965A1 (fr) * 2021-09-03 2023-03-09 Dr. Reddy’S Laboratories Limited Procédé d'obtention d'une composition d'anticorps purifiée
WO2023180523A1 (fr) * 2022-03-24 2023-09-28 Pieris Pharmaceuticals Gmbh Procédé de purification de protéines de fusion
WO2024249568A1 (fr) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Compositions d'anticorps anti-intégrine alpha4beta7 et procédés d'utilisation
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
WO2006026759A2 (fr) * 2004-09-03 2006-03-09 Genentech, Inc. Antagonistes anti-beta7 humanises et utilisations de ceux-ci
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
MX367097B (es) * 2011-05-02 2019-08-05 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI-A4ß7.
JP6592426B2 (ja) * 2013-03-15 2019-10-16 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 無塩条件下で疎水性相互作用クロマトグラフィーを使用するタンパク質精製
PL3116891T3 (pl) * 2014-03-10 2020-07-27 Richter Gedeon Nyrt. Oczyszczanie immunoglobuliny z zastosowaniem etapów wstępnego oczyszczania
WO2018104893A1 (fr) * 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Anticorps anti-alpha4-beta7 présentant une liaison à fcrn et/ou une demi-vie augmentées

Also Published As

Publication number Publication date
CN118909121A (zh) 2024-11-08
JP2022536659A (ja) 2022-08-18
AU2020290999A1 (en) 2022-02-03
CN118909120A (zh) 2024-11-08
CN118909119A (zh) 2024-11-08
CN114025843B (zh) 2026-01-09
AR119268A1 (es) 2021-12-09
CN114025843A (zh) 2022-02-08
JP7753105B2 (ja) 2025-10-14
EP3980119A4 (fr) 2023-06-07
WO2020252072A1 (fr) 2020-12-17
US20220259291A1 (en) 2022-08-18
PL439807A1 (pl) 2022-12-05
TW202112800A (zh) 2021-04-01
IL288830A (en) 2022-02-01
JP2025087720A (ja) 2025-06-10
EP3980119A1 (fr) 2022-04-13
BR112021024848A2 (pt) 2022-01-18
CA3143169A1 (fr) 2020-12-17
MX2021015302A (es) 2022-01-18

Similar Documents

Publication Publication Date Title
MA56132A (fr) Procédés de purification d'anticorps et compositions associées
EP3824096A4 (fr) Nouveaux anticorps et leurs procédés de préparation et d'utilisation
EP4367227A4 (fr) Compositions et procédés d'édition de génome efficace
EP2376656A4 (fr) Procédés de détermination de l'efficacité d'un traitement par glucocorticoïde de l' sophagite à éosinophiles
EP3921418A4 (fr) Compositions et procédés de séquençage d'acide nucléique
EP3911338A4 (fr) Compositions et procédés d'inhibition d'antigènes spécifiques de lignée
MA53015A (fr) Anticorps anti-sirp-bêta1 et procédés d'utilisation associés
EP3954696A4 (fr) Procédé de purification d'anticorps modifié en région fc
EP2224955A4 (fr) Compositions et procédés pour la prévention et le traitement de l'arthrite
EP3990031A4 (fr) Procédés de purification de virus adéno-associé
EP2091975A4 (fr) Anticorps de la famille anti-egfr, anticorps de la famille anti-egfr bispécifiques et leurs procédés d'utilisation
MA31502B1 (fr) Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation
EP2043620A4 (fr) Compositions et procédés destinés au traitement d'infections parasitaires
EP3280444A4 (fr) Procédés de purification d'anticorps hétérodimères multispécifiques mélangés à des espèces d'anticorps homodimères parentaux
EP3990191A4 (fr) Dispositif de purification d'air
MA53445A (fr) Procédés et compositions pour la modification de plantes
EP3645049A4 (fr) Anticorps multispécifiques et procédés de préparation et d'utilisation associés
EP4009778A4 (fr) Procédés et compositions pour la production de mycéliums ectomycorhiziens et leurs procédés d'utilisation
MA53391A (fr) Compositions pour l'agriculture et procédés associés
EP3980774A4 (fr) Compositions et procédés de détection d'auto-anticorps
EP3897717A4 (fr) Procédés de production d'anticorps hétérodimères
MA53811A (fr) Anticorps spécifiques à l'apoc3 humaine et du cynomolgus et procédés pour leur utilisation
MA55284A (fr) Procédés de production de compositions d'anticorps anti-tnf
EP3768281A4 (fr) Compositions et procédés d'activation de lymphocytes t et de cytokines
EP2254588A4 (fr) Procédés de préparation et composition de constructions de peptide utiles pour le traitement de la polyarthrite rhumatoïde